TrialCancer medicine2018

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.

Xiaojun Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.